Steward Partners Investment Advisory’s Aardvark Therapeutics AARD Stock Holding History

Steward Partners Investment Advisory’s Portfolio AARD Stock Details AARD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$15.6K	Buy	+4,150	New	+$43K	﹤0.01%	3350

Other funds holding AARD

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

TAM

TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Steward Partners Investment Advisory's AARD Position: Q1 2026 in Review

Steward Partners Investment Advisory opened a new position in Aardvark Therapeutics (AARD) in Q1 2026: 4,150 shares worth $15.6K. The stake represents ﹤0.01% of the portfolio and ranks #3350 among its holdings.

79 funds tracked by Wall St. Rank hold AARD as of Q1 2026.

Steward Partners Investment Advisory held 4,150 shares of Aardvark Therapeutics worth $15.6K as of Q1 2026.
Aardvark Therapeutics was a new Steward Partners Investment Advisory position in Q1 2026.
Aardvark Therapeutics made up ﹤0.01% of Steward Partners Investment Advisory's portfolio in Q1 2026, its #3350 holding.
79 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q1 2026.

Based on Steward Partners Investment Advisory's 13F filing for Q1 2026, filed 8 May 2026.